Pfizer has signed an agreement to license Sciwind Biosciences’ ecnoglutide for commercialization in mainland China, with potential payments totaling as much as $495 million if certain milestones are achieved.
Ecnoglutide is an injectable GLP-1 receptor agonist that was approved in China in January to help control blood sugar in patients with type 2 diabetes mellitus. The therapy was cleared by China’s National Medical Products Administration. In addition to its diabetes indication, Sciwind has stated that the drug can also address long-term weight management needs.
According to data reported by the company from a Chinese population, treatment with ecnoglutide resulted in a 15.1% placebo-adjusted reduction in body weight. Nearly 93% of treated patients achieved what the company described as clinically meaningful weight loss. Sciwind also confirmed that China’s regulatory authorities have accepted a marketing authorization application for ecnoglutide for chronic weight management.
Under the terms of the agreement, Sciwind will receive an upfront payment from Pfizer, although the amount was not disclosed. The biotech is also eligible for additional payments tied to regulatory and sales-related milestones, bringing the total potential value of the deal to $495 million. The agreement grants Pfizer exclusive commercialization rights for ecnoglutide in mainland China.
In a statement, Sciwind said the deal represents “an important first step to advance Pfizer’s global strategy in the metabolic field in China.” The company noted that ecnoglutide belongs to the GLP-1 receptor agonist class, an area that has seen investment from drugmakers including Novo Nordisk, Eli Lilly, Innovent Biologics, and Guangzhou Innogen.
The licensing agreement adds to a series of transactions by Pfizer in the metabolic and obesity treatment space. Late last year, the company agreed to acquire Metsera after a competitive bidding process. Pfizer initially offered $4.9 billion in September 2025. Subsequently, Novo Nordisk made an $8.5 billion bid, leading to a dispute that involved lawsuits and scrutiny from the U.S. Federal Trade Commission. Pfizer ultimately increased its offer to approximately $10 billion and completed the acquisition.
Through the Metsera acquisition, Pfizer obtained PF’3944, a long-acting GLP-1 injectable. Earlier this month, the company received Phase 3 data for the candidate showing a 12.3% placebo-adjusted reduction in body weight at 28 weeks. Analysts at BMO Capital Markets described the results as appearing competitive with obesity drugs currently on the market, and Pfizer is advancing the therapy into late-stage development.
In December 2025, Pfizer also entered into a collaboration with China’s YaoPharma, licensing an experimental GLP-1 drug in early development. That agreement included a $150 million upfront payment and could reach up to $1.9 billion in value when factoring in development, regulatory, and commercial milestones.
A Pfizer spokesperson declined to comment on the size of the upfront payment related to the Sciwind deal, as well as on the timing of ecnoglutide’s launch and its pricing. Unlike Novo Nordisk’s Ozempic, Eli Lilly’s Mounjaro, and Innogen’s efsubaglutide alfa, ecnoglutide will not be covered under China’s state-run health insurance scheme for type 2 diabetes treatment.
Sciwind Signs Strategic Licensing Agreement with Pfizer
Pfizer has entered into a significant licensing agreement with Sciwind Biosciences to commercialize Sciwind’s investigational GLP-1 receptor agonist, ecnoglutide, in China. The Sciwind deal is valued at up to $495 million, including upfront payments, development milestones, and commercial incentives.
Under the terms of the Sciwind agreement, Pfizer will obtain exclusive rights to market and distribute ecnoglutide across mainland China. Sciwind will remain responsible for certain development and manufacturing activities, reinforcing Sciwind’s role as an innovation-driven biotech company.
By collaborating with Pfizer, Sciwind gains access to established commercialization infrastructure, regulatory expertise, and an extensive distribution network. This Sciwind alliance is expected to accelerate patient access to next-generation metabolic therapies.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
